- Molecular NameMifepristone
- SynonymMifepriston; Mifepristona [Spanish]; mifepristone; Mifepristonum [Latin]; RU486
- Weight417.593
- Drugbank_IDDB00834
- ACS_NO84371-65-3
- Show 2D model
- LogP (experiment)4.368
- LogP (predicted, AB/LogP v2.0)4.72
- pkaN/A
- LogD (pH=7, predicted)4.72
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-6.34
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds3
- TPSA40.54
- StatusFDA approved
- AdministrationN/A
- PharmacologyA synthetic steroid compound used as a pharmaceutical. It is used as an abortifacient in the first two months of pregnancy, and in smaller doses as an emergency contraceptive.
- Absorption_value90.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability69.0
- Protein binding98.0
- Volume of distribution (VD)25.7 L (8 L after 280 mg intravenous dose)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life18 h; also reported as 54 to 90 h, possibly due to cross-reacting of the metabolites.
- ExcretionFecal: 83%; Renal: 9%
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityNearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy manstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.
- LD50 (rat)N/A
- LD50 (mouse)N/A